AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00235287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: candesartan and enalapril
Description: 8 weeks of treatment with Candesartan in incremental doses (4,8,16 mg), followed by 8 weeks of treatment with Enalapril in incremental doses (/5,10,20 mg). The treatment in the last 8 out of the 24 weeks is a combination of Candesartan in incremental doses (4,8,16 mg) and Enalapril 20 mg.
Study NCT00235287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: candesartan and enalapril
Description: 8 weeks of treatment with Enalapril in incremental doses (5,10,20 mg), followed by 8 weeks of treatment with Candesartan (4,8,16 mg). The treatment in the last 8 out of the 24 weeks is a combination of Candesartan 16 mg and Enalapril in incremental doses (5,10,20 mg)
Study NCT01174173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: ranolazine 1000 mg PO BID for 3 months
Study NCT02027948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutritional and functional assessments
Description: Patients will undergo nutritional \& functional assessments along the continuum of their chemoradiotherapy treatment. The initial assessment will be measurements of height, weight, \& baseline weight loss. Patients will receive chemotherapy \& radiation as per standard practice at MSKCC, which is induction chemotherapy for approximately 3 weeks, followed by concurrent chemoradiotherapy. A commonly used regimen is weekly carboplatin (AUC 2) with paclitaxel (50 mg/m2) \& radiation consisting of 5040 cGy over 28 fractions. Patients in this study will undergo assessments at three time points (at baseline, after induction chemotherapy, \& post-treatment.) At baseline, all patients will complete the functional assessment, dysphagia scale, \& Mini- Nutritional Assessment (MNA). According to the baseline MNA score, patients will be categorized as normal nutrition, at risk for malnutrition, or malnourished \& receive the appropriate intervention.
Study NCT03391414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium chloride
Description: 7% sodium chloride inhaled
Study NCT01896245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane 1,0
Description: anesthesia induction with propofol, remifentanil, and sevoflurane 1,0 MAC; afterwards tracheal intubation
Study NCT00323492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Current HAART regimen
Description: Maintain baseline regimen
Study NCT03082599 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Presbyopia and astigmatism correcting intraocular lens
Description: The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.
Study NCT03082599 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Presbyopia and astigmatism correcting intraocular lens
Description: The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.
Study NCT04926532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab is a humanized anti-PD-1 monoclonal antibody
Study NCT04926532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib is a multi-kinase inhibitor
Study NCT00363779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: An oral preparation given every 12 hours, 5-10 mg/kg/day in divided doses. Doses are adjusted to maintain a therapeutic level between 200-400 ng/ml. Levels will be checked twice weekly and once the patient has achieved steady state levels they shall be monitored once every 2 weeks. These therapeutic levels shall be maintained for 3 months.
Study NCT00363779 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Gene expression analysis
Description: A permutation test will be performed to examine whether the overall expression profile changes due to treatment. This will be done by comparing the number of significant genes to the distribution of this number if in fact there is no difference between pre-treatment and post-treatment gene expression.
Study NCT00363779 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Microarray analysis
Description: Gene expression profiling will be carried out on Affymetrix microarrays to compare pretreatment and posttreatment samples.
Study NCT03647449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric restriction via Plant-based meals
Description: Participants' caloric intake will be limited to 800-900 kcal/day.
Study NCT03647449 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant-based meal
Description: Participants will be eating \~900 kcal/day in pre-prepared plant-based meals.
Study NCT03155399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive based training (PBT)
Description: During the PBT patient will stay in supine position with the upper limbs positioned in symmetric posture. He/She will be asked to move both limbs with the same frequency performing bilateral flexion-extension of one of the upper limb districts according to the available free ROM of the target joint. The movement execution of the affected arm will be supported by the physiotherapist performing passive movement at the same rhythm, as the one executed with the unaffected side. Patient will be asked to focus the attention on the movement performed against gravity, which will be reinforced by a verbal command. Afterwards, the physiotherapist will fully support movement execution coherently with the patient's movement initialization. The active movement performed voluntarily by the patient with unaffected limb will be considered as the reference movement, that the physiotherapist has to emulate passively, by synchronization of passive movement executed in phase with the affected side.
Study NCT03155399 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional neuromotor treatment (CNT).
Description: The patients randomized to the CNT group will be asked to perform exercises for postural control, exercises for hand pre-configuration, exercises for the stimulation of manipulation and functional skills, exercises for proximal-distal coordination. All the exercises will be performed with or without the assistance of a physiotherapist. The upper limb motricity will be trained with progressive complexity.
Study NCT01542983 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief behavioral treatment for insomnia and bright light
Description: daily bright light exposure; 2 sessions for insomnia
Study NCT01542983 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual
Description: Standard treatment for fatigue and insomnia
Study NCT01042132 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the effect of delayed intramedullary reaming
Description: in one group intramedullary reaming and nailing is performed immediately, femoral fractures in the second group are external fixated and than secondary nailed.
Study NCT01042132 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the reaming of the femoral canal is performed with two different reaming devices
Description: the reaming of the femoral canal is performed with two different reaming devices; a traditional reamer (TR)and the reamer-irrigator-aspirator (RIA)
Study NCT01381341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linifanib
Description: QD on Day 1 of Periods 1 and 2
Study NCT01653106 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: Receive shaved ice
Study NCT01653106 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy
Description: Receive shaved ice
Study NCT01896245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane 1,2
Description: anesthesia induction with propofol, remifentanil, and sevoflurane 1,2 MAC; afterwards tracheal intubation
Study NCT01896245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane 1,4
Description: anesthesia induction with propofol, remifentanil, and sevoflurane 1,4 MAC; afterwards tracheal intubation
Study NCT05018104 — intervention group
Intervention type: OTHER
Intervention: This is not an interventional study
Description: This study utilizes data from the St. Paul's Hospital Peripheral Nerve Block Database.
Study NCT00363779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory biomarker analysis
Description: Analysis of differential gene expression profiles in patients with LGL leukemia treated with cyclosporine.
Study NCT00913809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desipramine HCL 100 mg Tablets Cord Laboratories
Study NCT00913809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norpramin 100 mg Tablets Merrell Dow Pharmaceuticals, Inc
Study NCT03828812 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast promotion
Description: Recommendation of having breakfast daily
Study NCT03828812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breakfast promotion
Description: Recommendation of having breakfast daily
Study NCT03828812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nighttime snack reduction
Description: Recommendation of reducing frequency of nighttime snacking
Study NCT03828812 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nighttime snack reduction
Description: Recommendation of reducing frequency of nighttime snacking
Study NCT01911273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03446962
Description: PF 03446962 7 mg/kg, IV, every 2 weeks, until disease progression, patient refusal or unacceptable toxicity, whichever occurs first
Study NCT01911273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life
Study NCT04404647 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation
Description: The IRE procedure will be carried out as ultrasound guided technique either percutaneously or during laparotomy. Needle spacing and electrical pulse delivery will be performed in a standardized way.
Study NCT02441933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taxane plus carboplatin
Description: Doxorubicin (60 mg/m2) IV + cyclophosphamide (600 mg/m2) IV every 3 weeks for 4 cycles followed by taxane plus carboplatin for 4 cycles The taxane plus carboplatin regimen can be selected based on the investigator's discretion from among the following two regimens.~* Docetaxel (75 mg/m2) IV plus carboplatin (AUC 5) IV every 3 weeks for 4 cycles~* Paclitaxel (80 mg/m2) IV weekly for 12 doses plus carboplatin (AUC 5) IV every 3 weeks for 4 cycles
Study NCT02441933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxane
Description: Doxorubicin (60 mg/m2) IV + cyclophosphamide (600 mg/m2) IV every 3 weeks for 4 cycles followed by taxane for 4 cycles The taxane regimen can be selected at the investigator's discretion from among the following two regimens.~* Docetaxel (75 mg/m2) IV every 3 weeks for 4 cycles~* Paclitaxel (80 mg/m2) IV weekly for 12 doses
Study NCT00329407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate (Topamax)
Description: Medication Dosing Schedule: Days 1-3 50 mg q PM Days 4-7 50 mg BID Days 8-11 50 mg q AM \& 100 mg q PM Days 12-15 100mg BID Days 16-19 100 mg q AM \& 150 mg q PM Days 20-23 150 mg BID Days 24-27 150 mg qAM \& 200 mg q PM Days 28-70 200 mg BID Days 71-77 150 mg BID Days 78-84 100mg BID Days 85-87 50 mg BID Days 88-91 50 mg qPM
Study NCT04982055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadroparin (intravenous Infusion)
Description: Intravenous route of administration over a 4-hours infusion of nadroparin 3800 IU
Study NCT04982055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nadroparin (subcutaneous group)
Description: Subcutaneous route of administration of nadroparin 3800 IU
Study NCT05225142 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified minimally invasive surgery
Description: Surgical intervention alone
Study NCT05225142 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified minimally invasive surgery
Description: Surgical intervention alone
Study NCT05225142 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified minimally invasive surgery with enamel matrix derivative
Description: Surgical intervention with local application of regenerative biomaterial
Study NCT05225142 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified minimally invasive surgery with enamel matrix derivative and bone replacement graft
Description: Surgical intervention with local application of regenerative biomaterial and bone replacement graft
Study NCT02374645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volitinib
Description: 600mg or 800mg QD: Patients may continue to receive the treatment as long as they are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Study NCT02374645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: 250mg QD: Patients may continue to receive the treatment as long as they are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Study NCT02831166 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transradial primary percutaneous coronary intervention
Description: Transradial coronary angiography will be performed by the Judkins technique using 6 French diameter sheaths and pre-molded catheters for selective catheterization of left and right coronary arteries. Primary percutaneous coronary intervention with stent deployment will be indicated when a culprit lesion is identified, with high probability of angiographic success, being ideally performed immediately after coronary angiography Procedures will be performed according to recommendations of current guidelines. To achieve hemostasis in the transradial approach, a radial compression device will be applied, to maintain patent antegrade flow.
Study NCT02831166 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transfemoral primary percutaneous coronary intervention
Description: Transfemoral coronary angiography will be performed by the Judkins technique using 6 French diameter sheaths and pre-molded catheters for selective catheterization of left and right coronary arteries. Primary percutaneous coronary intervention with stent deployment will be indicated when a culprit lesion is identified, with high probability of angiographic success, being ideally performed immediately after coronary angiography Procedures will be performed according to recommendations of current guidelines. A vascular closure device will be used to achieve hemostasis in the transfemoral approach, preceded by systematic performance of femoral angiography and maintaining absolute bed rest for 60 minutes.
Study NCT01653106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Participate in PROMS
Study NCT01653106 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Participate in PROMS
Study NCT01653106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01653106 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies
Study NCT03576118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block
Description: Deep neuromuscular block using high dose rocuronium and 8 mmHg pneumoperitoneum
Study NCT03576118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moderate neuromuscular block
Description: Moderate neuromuscular block using moderate dose rocuronium and 12-15 mmHg pneumoperitoneum
Study NCT02718885 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inulin
Description: Females will ingest 2 doses of 5g/inulin for a total of 10g/inulin/day for four weeks Males will ingest 2 doses of 7.5g/inulin for a total of 15g/inulin/day for four weeks
Study NCT01911273 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will consist of Saline (0.9% w/v Sodium Chloride Injection, USP or NS)
Study NCT01911273 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care
Description: BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
Study NCT03733821 — intervention group
Intervention type: DEVICE
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Non-invasive brain stimulation tool
Study NCT03143699 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate Feedback
Description: Students will be trained to measure blood pressure in the same way, with a brief 4-hour theoretical-practical intervention. After the training, students will measure the blood pressure of a standardized patient and observers will evaluate them using a checklist. After that, students from the intervention group will receive an immediate feedback based on the previous literature. Briefly, feedback will be based on what was directly observed and will be phrased in non-judgmental language, following the Pendleton model.
Study NCT00566150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: Flexible dose up to 2500mg per day, for 6 weeks.
Study NCT00566150 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Flexible dose up to 2500mg per day, for 6 weeks.
Study NCT01648855 — intervention group
Intervention type: OTHER
Intervention: Biological samples
Description: To measure the levels of sFlt1, angiogenic and antiangiogenic factors at birth in maternal blood, umbilical cord blood and in the amniotic fluid
Study NCT02347189 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Melody Transcatheter Pulmonary Valve PB1016
Study NCT03830944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Assessment of complete blood count, biochemistry, inflammatory biomarkers, adhesion molecules
Study NCT03830944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: transthoracic echocardiography
Description: Assessment of the ventricular anatomy, size, function, speckle tracking, myocardial strain, valvular function.
Study NCT03830944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Late Gadolinium-Enhancement Cardiac Magnetic Resonance
Description: Assessment of the ventricular anatomy, function, viability, degree of fibrosis, quantification of infarct size, mass.
Study NCT03830944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary Angio Computed Tomography
Description: Assessment of coronary plaque anatomy, morphology, vulnerability features, quantification of epicardial adipose tissue
Study NCT02718885 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Maltodextrin
Description: Females will ingest 2 doses of 5g/maltodextrin for a total of 10g/maltodextrin/day for four weeks Males will ingest 2 doses of 7.5g/maltodextrin for a total of 15g/maltodextrin/day for four weeks
Study NCT03122860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04690
Description: Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
Study NCT03797300 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spry Loop Band
Description: Loop band measures pulse oximetry and respiration rate
Study NCT02300181 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03122860 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
Study NCT02300181 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis var natto DC-15
Study NCT03460912 — intervention group
Intervention type: DEVICE
Intervention: Bipolar and monopolar probes (SPESS MEDICA S.r.l. Via Buccari 16153 Genova (GE), Italy) administered to all participants.
Description: Bipolar and monopolar probes (SPESS MEDICA S.r.l. Via Buccari 16153 Genova (GE), Italy) administered to all participants.They compared each others(bipolar vs monopolar) via amplitudes and latency values.
Study NCT04246632 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CapsoCam Colon Capsule Endoscopy
Description: CapsoCam® Colon is intended to provide visualization of the colon and the detection of colon polyps in adults.
Study NCT04725487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard integration program with social and health promoting intervention
Description: * Basic language course, internships, courses in Labour market knowledge and Danish culture~* Physical activity workshops~* Community gardening (garden workshops)~* Entrepreneurship course~* MindSpring course~* Family excursions~* Danish language workshops
Study NCT04725487 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard integration program
Description: Standard integration program (basic language course, internships, courses in Labour market knowledge and Danish culture)
Study NCT03122860 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Healthcare professional-administered intra-articular injection performed once on Day 1 of the study